Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis
By Amit G. Singal, A. Pillai, Jasmin A. Tiro. PLoS Medicine, 2014
740 citations recorded by the source corpus.
Amit Singal and colleagues conducted a systematic review of the evidence that surveillance for hepatocellular carcinoma in patients with cirrhosis improves early detection, receipt of curative treatment, and overall survival. Please see later in the article for the Editors' Summary
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/f83f021deadbe7a20e5d11c789f5a11d689759eb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- R. Finn
- Jorge Marrero
- Lewis R. Roberts
- Andrew X. Zhu
- Claude B. Sirlin
- J. Heimbach
- L. Kulik
- Michael M. Abecassis
In Hepatology
- R. Finn
- Jorge Marrero
- Lewis R. Roberts
- Andrew X. Zhu
- Claude B. Sirlin
- J. Heimbach
- L. Kulik
- M. H. Murad
Citations in the corpus
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “US, with or without AFP, is recommended for surveillance because most of the studies showed a benefit of the combination of US and AFP in improving OS.”
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, background): “US, with or without AFP, is recommended for surveillance because most of the studies showed a benefit of the combination of US and AFP in improving OS.”
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[56,58,59] These studies have several potential limitations, including lead time bias, length time bias, risk of overdiagnosis, and residual confounding, although the benefits of surveillance remained in studies that statistically accounted for these biases.”
- AASLD guidelines for the treatment of hepatocellular carcinoma (2018, methodology): “The evidence profile of surveillance for HCC is included in Supporting Table 1, which uses the data from a recent systematic review on surveillance.((13)) There were no randomized controlled trials (RCTs) of surveillance in patients with cirrhosis.”